Point72 Asia Singapore Pte. Ltd. Invests $52,000 in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Point72 Asia Singapore Pte. Ltd. purchased a new stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 17,115 shares of the company’s stock, valued at approximately $52,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Corton Capital Inc. purchased a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter valued at approximately $32,000. Captrust Financial Advisors acquired a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter worth $33,000. Prudential Financial Inc. purchased a new position in shares of Zentalis Pharmaceuticals during the fourth quarter valued at $39,000. Cerity Partners LLC acquired a new position in Zentalis Pharmaceuticals during the fourth quarter valued at $40,000. Finally, Ieq Capital LLC purchased a new stake in Zentalis Pharmaceuticals in the 4th quarter worth about $46,000.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ZNTL. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a research note on Thursday. Wedbush reaffirmed a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday. UBS Group dropped their price objective on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, Wells Fargo & Company decreased their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Price Performance

ZNTL opened at $1.26 on Monday. The company has a market capitalization of $90.66 million, a P/E ratio of -0.51 and a beta of 1.81. The firm’s fifty day moving average price is $1.44 and its two-hundred day moving average price is $2.33. Zentalis Pharmaceuticals, Inc. has a fifty-two week low of $1.01 and a fifty-two week high of $13.00.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, meeting the consensus estimate of ($0.67). On average, equities research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other news, Director Scott Dunseth Myers bought 21,000 shares of Zentalis Pharmaceuticals stock in a transaction dated Wednesday, April 30th. The shares were bought at an average price of $1.40 per share, for a total transaction of $29,400.00. Following the purchase, the director now owns 281,192 shares of the company’s stock, valued at approximately $393,668.80. This trade represents a 8.07% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.90% of the company’s stock.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.